Search Results
Marwan G. Fakih, MD, regarding outcomes from the AMG 510 study
Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers
Marwan Fakih, MD, considers implications from the AMG 510 trial
Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in solid tumors
Dr. Fakih on the Safety Profile of AMG 510 in KRAS G12C-Mutated CRC
AMG 510 for targeting KRAS G12C mutant solid tumours
Marwan G. Fakih, MD, on whether KRAS amplification predicts resistance to EGFR therapies
Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC
Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients
ASCO 2019: Marwan Fakih, M.D.
Marwan G. Fakih, MD, describes the role of KRAS inhibitors in colorectal cancer
Dr. Fakih: Comorbidity Condition as a Factor in Treatment Decision
